Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 6/20 | 0.47 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.44 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274106 | 1.00 | SNCA (0.47) | SNCAIGF2BP2KCNK2KCNK10TRPV1 | |
| SCHEMBL27848573 | 0.90 | IGF2BP2 (0.46) | SNCAIGF2BP2KCNK2KCNK10TRPV1 | |
| SCHEMBL2272483 | 0.88 | IGF2BP2 (0.57) | SNCAIGF2BP2KCNK2KCNK10TRPV1 | |
| SCHEMBL2272471 | 0.88 | IGF2BP2 (0.57) | SNCAIGF2BP2KCNK2KCNK10TRPV1 | |
| SCHEMBL2270355 | 0.87 | SNCA (0.46) | SNCANPC1RAB9AAPPKDM4E | |
| SCHEMBL2270348 | 0.87 | SNCA (0.46) | SNCANPC1RAB9AAPPKDM4E | |
| SCHEMBL2276669 | 0.83 | SNCA (0.59) | SNCANPC1RAB9AAPPKDM4E | |
| SCHEMBL2276677 | 0.83 | SNCA (0.59) | SNCANPC1RAB9AAPPKDM4E | |
| SCHEMBL2275290 | 0.82 | SNCA (0.45) | SNCANPC1RAB9AKDM4EMAPK1 | |
| SCHEMBL2275293 | 0.82 | SNCA (0.45) | SNCANPC1RAB9AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | SNCA 4741/4885IGF2BP2 4173/4885KCNK2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.